Eliquis, Bydureon Launches Still A Wait-And-See Story For Bristol
This article was originally published in The Pink Sheet Daily
Executive Summary
Investors are focused on the launch of both drugs, which are expected to contribute meaningfully to Bristol’s return to growth, as well as on nivolumab, a promising anti-PD-1 in development for cancer. Few conclusions can be drawn on any of those fronts from the company’s first quarter financial update.